Neal A Chatterjee1, Jagmeet P Singh2, Jackie Szymonifka3, Roderick C Deaño3, Wai-Ee Thai4, Bryan Wai4, James K Min3, James L Januzzi1, Quynh A Truong5. 1. Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 2. Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 3. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, NY, United States. 4. Cardiac MR PET CT Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 5. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, NY, United States. Electronic address: qat9001@med.cornell.edu.
Abstract
BACKGROUND: Despite the benefit of CRT in select patients with heart failure (HF), there remains significant need for predicting those at risk for adverse outcomes for this effective but costly therapy. CysC, an emerging marker of renal function, is predictive of worsening symptoms and mortality in patients with HF. This study assessed the utility of baseline and serial measures of cystatin C (CysC), compared to conventional creatinine-based measures of renal function (estimated glomerular filtration rate, eGFR), in predicting clinical outcomes following cardiac resynchronization therapy (CRT). METHODS: In 133 patients, we measured peripheral venous (PV) and coronary sinus (CS) CysC concentrations and peripheral creatinine levels at the time of CRT implant. Study endpoints included clinical response to CRT at 6 months and major adverse cardiac events (MACE) at 2 years. RESULTS: While all 3 renal metrics were predictive of MACE (all adjusted p ≤ 0.02), only CysC was associated with CRT non-response at 6 months (adjusted odds ratio 3.6, p = 0.02). CysC improved prediction of CRT non-response (p ≤ 0.003) in net reclassification index analysis compared to models utilizing standard renal metrics. Serial CysC > 1mg/L was associated with 6-month CRT non-response and reduced 6-minute walk distance as well as 2-year MACE (all p ≤ 0.04). CONCLUSION: In patients undergoing CRT, CysC demonstrated incremental benefit in the prediction of CRT non-response when compared to standard metrics of renal function. Baseline and serial measures of elevated CysC were predictive of CRT non-response and functional status at 6 months as well as long-term clinical outcomes.
BACKGROUND: Despite the benefit of CRT in select patients with heart failure (HF), there remains significant need for predicting those at risk for adverse outcomes for this effective but costly therapy. CysC, an emerging marker of renal function, is predictive of worsening symptoms and mortality in patients with HF. This study assessed the utility of baseline and serial measures of cystatin C (CysC), compared to conventional creatinine-based measures of renal function (estimated glomerular filtration rate, eGFR), in predicting clinical outcomes following cardiac resynchronization therapy (CRT). METHODS: In 133 patients, we measured peripheral venous (PV) and coronary sinus (CS) CysC concentrations and peripheral creatinine levels at the time of CRT implant. Study endpoints included clinical response to CRT at 6 months and major adverse cardiac events (MACE) at 2 years. RESULTS: While all 3 renal metrics were predictive of MACE (all adjusted p ≤ 0.02), only CysC was associated with CRT non-response at 6 months (adjusted odds ratio 3.6, p = 0.02). CysC improved prediction of CRT non-response (p ≤ 0.003) in net reclassification index analysis compared to models utilizing standard renal metrics. Serial CysC > 1mg/L was associated with 6-month CRT non-response and reduced 6-minute walk distance as well as 2-year MACE (all p ≤ 0.04). CONCLUSION: In patients undergoing CRT, CysC demonstrated incremental benefit in the prediction of CRT non-response when compared to standard metrics of renal function. Baseline and serial measures of elevated CysC were predictive of CRT non-response and functional status at 6 months as well as long-term clinical outcomes.
Authors: Quynh A Truong; James L Januzzi; Jackie Szymonifka; Wai-ee Thai; Bryan Wai; Zachary Lavender; Umesh Sharma; Ryan M Sandoval; Zachary S Grunau; Sandeep Basnet; Adefolakemi Babatunde; Olujimi A Ajijola; James K Min; Jagmeet P Singh Journal: Heart Rhythm Date: 2014-07-08 Impact factor: 6.343
Authors: Eszter Maria Vegh; Jagdesh Kandala; Mary Orencole; Gaurav A Upadhyay; Ajay Sharma; Alexandra Miller; Bela Merkely; Kimberly A Parks; Jagmeet P Singh Journal: Am J Cardiol Date: 2014-02-12 Impact factor: 2.778
Authors: A Separham; L Pourafkari; B Kazemi; Y Haghizadeh; F Akbarzadeh; M Toufan; H Sate; N D Nader Journal: Herz Date: 2017-10-09 Impact factor: 1.443
Authors: Quynh A Truong; Jackie Szymonifka; James L Januzzi; Jigar H Contractor; Roderick C Deaño; Neal A Chatterjee; Jagmeet P Singh Journal: Heart Rhythm Date: 2018-12-24 Impact factor: 6.343